Clinical Trial Update: Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer [Phase 3]

View source ↗

Summary

This Clinical Trials update reports a Phase 3 study evaluating chiauranib in combination with weekly paclitaxel for platinum-refractory or platinum-resistant re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Chiauranib (Chiauranib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Ovarian Cancer, Relapsed or Refractory | Phase 3 | Status: RECRUITING